WHO Grants Emergency Use Listing for Japan’s LC16m8 Mpox Vaccine for Children
The World Health Organization (WHO) has added Japan’s LC16m8 mpox vaccine to its emergency use list. This vaccine is the second one to receive this status since the WHO raised concerns about mpox outbreaks in Africa.
The listing allows countries to obtain the vaccine and provides an opportunity to vaccinate children, especially in areas like the Democratic Republic of the Congo (DRC) and Burundi, where the virus has affected many. Japan has donated 3.05 million doses of the vaccine, along with the necessary needles for vaccination, making it the largest donation amid the ongoing outbreaks in Africa.
The WHO recommends LC16m8 for individuals over 1 year old. It is administered as a single dose using a bifurcated needle. The vaccine is not recommended for pregnant women or individuals with weakened immune systems, including some people with HIV.
How does Japan’s donation of the LC16m8 vaccine impact vaccination efforts in high-risk regions?
Interview with Dr. Hiroshi Tanaka, Vaccine Specialist at the World Health Organization
News Directory 3: Thank you for joining us, Dr. Tanaka. The World Health Organization has recently added Japan’s LC16m8 mpox vaccine to its emergency use list. Can you explain the significance of this addition?
Dr. Tanaka: Thank you for having me. The emergency use listing of LC16m8 is a crucial step in our ongoing battle against mpox, particularly following the alarming outbreaks in Africa. This vaccine represents an important tool that expands our immunization options and is particularly vital for vulnerable populations, including children in high-risk areas like the Democratic Republic of the Congo and Burundi.
News Directory 3: What makes LC16m8 unique compared to other vaccines?
Dr. Tanaka: One of the main advantages of LC16m8 is its simple administration as a single dose using a bifurcated needle, which makes it user-friendly in low-resource settings. Furthermore, it has been specifically recommended for individuals over the age of one, filling a critical gap in vaccination options for younger populations.
News Directory 3: Can you elaborate on the WHO’s recommendations regarding this vaccine, particularly concerning specific groups?
Dr. Tanaka: Absolutely. The WHO recommends LC16m8 for individuals aged one and older. However, it is important to note that it is not advisable for pregnant women or those with weakened immune systems, including certain individuals living with HIV. This targeted approach ensures we are effectively protecting those who are most likely to benefit from the vaccination without exposing vulnerable groups to unnecessary risks.
News Directory 3: Japan has donated a significant number of doses and the necessary needles for vaccination. How do you see this donation impacting public health efforts in affected regions?
Dr. Tanaka: Japan’s generous donation of 3.05 million doses of the LC16m8 vaccine is a massive boost for public health efforts in regions like the DRC and Burundi. This significant contribution not only allows for large-scale vaccination but also underscores international solidarity in addressing health crises. By vaccinating children and other at-risk populations, we can substantially lessen the burden of mpox outbreaks.
News Directory 3: what message would you like to convey to the public regarding the mpox vaccine and preventive measures?
Dr. Tanaka: My message would be one of hope and encouragement. The addition of LC16m8 to the WHO’s emergency use list signifies progress and the potential for better health outcomes in affected communities. It is crucial for individuals, especially in regions where mpox is prevalent, to stay informed and engage with local health authorities about vaccination opportunities and preventive measures. Together, we can work towards controlling and ultimately eradicating mpox. Thank you for this important conversation.
News Directory 3: Thank you, Dr. Tanaka, for sharing your insights on this critical public health development.
Yukiko Nakatani, a WHO official, stated that the emergency use listing of this vaccine is an important advancement in the fight against mpox. It offers a new way to protect all populations, including children. Currently, the authorized vaccine for those aged 12 and older is Bavarian Nordic’s Jynneos.